Update on ovarian hyperstimulation syndrome: Part 2 - Clinical signs and treatment

International Journal of Fertility and Women's Medicine

Volumn 52, Issue 2-3, 2007, Pages 69-81

  Binder, Helge ^a   Dittrich, Ralf ^a   Einhaus, Friedrich ^a   Krieg, Jürgen ^a   Müller, Andreas ^a   Strauss, Richard ^a   Beckmann, Matthias W ^a   Cupisti, Susanne ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

OHSS; Predisposition; Prophylaxis; Treatments

Indexed keywords

ABDOMINAL PAIN; ASCITES; CASE REPORT; FEMALE; FERTILIZATION IN VITRO; HOSPITALIZATION; HUMAN; METHODOLOGY; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATHOLOGY; PRIMARY PREVENTION; REVIEW; RISK FACTOR; VULVA; WOMEN'S HEALTH;

ABDOMINAL PAIN; ASCITES; FEMALE; FERTILIZATION IN VITRO; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PRIMARY PREVENTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VULVA; WOMEN'S HEALTH;

EID: 42949086920     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Keck C, Neulen J, Behre HM, et al eds. Praxis der Frauenheilkunde, vol. 1: Endokrinologie, Reproduktionsmedizin, Andrologie. 2nd ed. Stuttgart: Thieme, 2002.
2. Geisthövel F, Christ L, Haibt L, et al: Assisted reproductive techniques: risks, contraindications, prognostic factors, therapeutic strategies. Andrologia 35: 168-169, 2003.
3. Enskog A, Henriksson M, Unander M, et al: Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 71: 808-814, 1999. (Pubitemid 29206902)
4. Neulen J: Das ovarielle Überstimulationssyndrom. Reproduktionsmedizin 17: 149-152, 2001.
5. Kissler S, Siebzehnrübl E, Kaufmann M: Von der Pathophysiologie und Prävention des ovariellen Überstimulationssyndroms (OHSS) bis zur stadiengerechten Therapie. Geburtshilfe Frauenheilkd 62:1155-1161, 2002. (Pubitemid 36069440)
6. Schubert J, Merz M, Distler W: Das ovarielle Ü berstimulationssyndrom. Gynäkologe 35:363-371, 2002.
7. Nakamura Y, Takasaki A, Sugino N, et al: Studies on the effects of initial injection doses of follicle stimulating hormone on the pregnancy and the ovarian hyperstimulation syndrome incidence in polycystic ovarian syndrome patients. Reprod Med Biol 2:63-67, 2003.
8. Thomas K, Searle T, Quinn A, et al: The value of routine estradiol monitoring in assisted conception cycles. Acta Obstet Gynecol Scand 81:551-554, 2002. (Pubitemid 34628085)
9. Ho HY, Lee RKK, Lin MH, et al: Estradiol level on day 9 as a predictor of risk for ovarian hyperresponse during controlled ovarian hyperstimulation. J Assist Reprod Genet 20:222-226, 2003.
10. Kahraman S, Yakin K, Vanlioglu F, et al: Metformin as an adjuvant therapy in patients with polycystic ovaries undergoing controlled ovarian stimulation. Hum Reprod 18: 40xviii-42xviii, 115, 2003.
11. Yarali H, Yildiz BO, Demirol A, et al: Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 17: 289-294, 2002. (Pubitemid 34168428)
12. Chang AS, Odem RR, Ratts VS: Addition of Metformin with gonadotropin stimulation in PCOS patients. Fertil Steril 80 (Suppl 3):S110-111, 2003.
13. Vanlioglu F, Kahraman S, Karlikaya G, et al: Effect of metformin on subgroups of patients with polycystic ovaries undergoing controlled ovarian stimulation for assisted reproduction. Fertil Steril 80 (Suppl 3):S111, 2003.
14. Delvigne A, Kostyla K, De Leener A, Lejeune B, Cantiniaux B, Bergmann P, Rozenberg S. Metabolic characteristics of women who developed ovarian hyperstimulation syndrome. Hum Reprod 17:1994-1996, 2002.
15. Vanky E, Kjorod SB, Maesel A, et al: Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome. Fertil Steril 81:459-462, 2004.
16. Avril C, Bastite L, Chaput-Toupin E, et al: Does extreme obesity have an impact on ovarian response and outcome of infertile women included in IVF programs? Fertil Steril 80 (Suppl 3):S178-179, 2003.
17. Kol S: Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent! Hum Reprod 18:1557-1558, 2003.
18. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 81: 1-5, 2004. (Pubitemid 38058315)
19. Itskovitz-Eldor J, Kol S, Mannaerts B: Use of single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing controlled ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 15:1965-1968, 2000.
20. Ludwig M, Doody KJ, Doody KM: Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 79: 1051-1059, 2003. (Pubitemid 36547837)
21. Ludwig M, Diedrich K: Evaluation of an optimal luteal phase support protocol in IVF. Acta Obstet Gynecol Scand 80:452-466, 2001. (Pubitemid 32473055)
22. Levinsohn-Tavor O, Friedler S, Schachter M, et al: Coasting - what is the best formula? Hum Reprod 18:937-940, 2003.
23. Tozer AJ, Iles RK, Iammarrone E, et al: The effects of "coasting" on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Hum Reprod 19:522-528, 2004.
24. Chen CD, Chao KH, Yang JH, et al:. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril 80:86-90, 2003.
25. Delvigne A, Rozenberg S: Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 9:77-96, 2003. (Pubitemid 36305585)
26. Gokmen O, Ugur M, Ekin M, et al: Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol 96:187-192, 2001. (Pubitemid 32522558)
27. Ben-Chetrit A, Eldar-Geva T, Gal M, Huerta M, et al: The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod 16:1880-1884, 2001.
28. Ando H, Furugori K, Shibata D, et al: Dual rennin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum Reprod 18: 1219-1222, 2003. (Pubitemid 36740567)
29. McDonough PG: Vascular endothelial growth factor - mediator of OHSS? Fertil Steril 79:1466-1467, 2003.
30. Endo T, Honnma H, Hayashi T, et al: Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod 17:2548-2551, 2002. (Pubitemid 35174101)
31. Parsanezhad ME, Alborzi S, Pakniat M, et al: A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome. Fertil Steril 80:1151-1155, 2003. (Pubitemid 37377742)
32. Lainas T, Petsas G, Stavropoulou G, et al: Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertil Steril 78:529-533, 2002.
33. Gomez R, Gonzalez M, Simon C, et al: Tyrosine hydroxylase (TH) downregulation in hyperstimulated ovaries reveals the dopamine agonist bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS. Fertil Steril 80:S43-44, 2003.
34. Schröder AK, Schöpper B, Al-Hasani S, et al: Unilateral follicular aspiration and in-vitro maturation before contralateral oocyte retrieval: a method to prevent ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 110:186-189, 2003. (Pubitemid 37101317)
35. Amarin ZO: Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome: an aggressive, but perhaps life-saving procedure. Hum Reprod 18: 659-664, 2003.
36. Bellver J, Escudero E, Pellicer A: Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome (OHSS): ovarian mutilating surgery is not an option in the management of severe OHSS. Hum Reprod 18:1363-1367, 2003. (Pubitemid 36840939)
37. Oelsner G, Cohen SB, Soriano D, et al: Minimal surgery for twisted ischaemic adnexa can preserve ovarian function. Hum Reprod 18:2599-2602, 2003. (Pubitemid 37536626)
38. Abramov Y, Fatum M, Abrahamov D, et al: Hydroxyethyl starch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 75:1228-1230, 2001. (Pubitemid 32522627)
39. Kissler S, Neidhardt B, Siebzehnrübl E, et al: The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report. Eur J Obstet Gynecol Reprod Biol 99:131-134, 2001. (Pubitemid 32936946)
40. Abuzeid MI, Nassar Z, Massaad Z, et al: Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod 18:370-373, 2003. (Pubitemid 36236273)
41. Al-Ramahi M, Leader A, Claman P, et al: First report of a pigtail catheter to drain ascites associated with OHSS. Hum Reprod 18:2235, 2003. (Pubitemid 37265093)
42. Abuzeid MI: First report of a pigtail catheter to drain ascites associated with OHSS [author reply]. Hum Reprod 18:2235-a, 2003.
43. Stewart JA, Hamilton PJ, Murdoch AP: Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 1997; 12:2167-2173. (Pubitemid 27494024)
44. McGowan BMC, Kay LA, Perry DJ: Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization in a woman heterozygous for the prothrombin 3? UTR and factor V Leiden mutations. Am J Hematol 73:276-278, 2003. (Pubitemid 36898887)
45. Guideline: Management of ovarian hyperstimulation syndrome. Royal College of Obstetricians and Gynaecologists.
46. Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al: Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles Fert & Ster vol 85, no.1, 2006.
47. Endo T: Low-molecular weight dextran infusion is more effective for the treatment of hemoconcentration due to severe ovarian hyperstimulation syndrome than human albumin infusion. Fert & Ster 82:S1449, 2004.
48. Hitkari JA, Rowe TP, von Dadelszen P: Activated protein C and the ovarian hyperstimulation syndrome: possible therapeutic implications. Medical Hypothesis, 2006.
49. Deutsches IVF Register. Jahrbuch 2005. [German IVF-Register, volume 2005] Bad Segeberg, Germany: Deutsches IVF Register, 2005 (http://www.meb.uni-bonn. de/frauen/DIR-downloads/dirjahrbuch2005.pdf).